[{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"LAVA-051","moa":"CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"LAVA-051","moa":"CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LAVA-051","moa":"CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LAVA-051","moa":"CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LAVA-051","moa":"CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"LAVA-051","moa":"CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LAVA-051","moa":"CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LAVA-051","moa":"CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orca Therapeutics","sponsor":"CMX Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Microorganism","year":"2019","type":"Inapplicable","leadProduct":"ORCA-010","moa":"CD8+ T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orca Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Orca Therapeutics \/ CMX Research","highestDevelopmentStatusID":"7","companyTruncated":"Orca Therapeutics \/ CMX Research"},{"orgOrder":0,"company":"Orca Therapeutics","sponsor":"CMX Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"ORCA-010","moa":"CD8+ T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orca Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Orca Therapeutics \/ CMX Research","highestDevelopmentStatusID":"7","companyTruncated":"Orca Therapeutics \/ CMX Research"},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Glycostem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycostem Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Glycostem Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"MCLA-158","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Humanetics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Royal DSM \/ Humanetics","highestDevelopmentStatusID":"7","companyTruncated":"Royal DSM \/ Humanetics"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"LAVA-1207","moa":"Glutamate carboxypeptidase II (GCPII)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"LAVA-1207","moa":"||Glutamate carboxypeptidase II (GCPII)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Dutch Cancer Society","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"ISA101","moa":"HPV16 E6\/E7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISA Pharmaceuticals \/ Dutch Cancer Society","highestDevelopmentStatusID":"7","companyTruncated":"ISA Pharmaceuticals \/ Dutch Cancer Society"},{"orgOrder":0,"company":"Synaffix","sponsor":"Mersana Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2021","type":"Licensing Agreement","leadProduct":"XMT-1592","moa":"Sodium\/phosphate cotransporter 2B (SLC34A2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Synaffix","amount2":1,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1,"dosageForm":"Infusion","sponsorNew":"Synaffix \/ Mersana Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Synaffix \/ Mersana Therapeutics"},{"orgOrder":0,"company":"Byondis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BYON5667","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Byondis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Byondis \/ Undisclosed"},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"medac","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Glycostem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycostem Therapeutics \/ Medac","highestDevelopmentStatusID":"7","companyTruncated":"Glycostem Therapeutics \/ Medac"},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Glycostem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycostem Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Glycostem Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Glycostem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycostem Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Glycostem Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CellPoint","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellPoint","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.23000000000000001,"dosageForm":"Infusion","sponsorNew":"CellPoint \/ Galapagos","highestDevelopmentStatusID":"7","companyTruncated":"CellPoint \/ Galapagos"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Sofya Pintova","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Sofya Pintova","highestDevelopmentStatusID":"7","companyTruncated":"Royal DSM \/ Sofya Pintova"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
